These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23295318)

  • 21. Should total number of lymph nodes be used as a quality of care measure for stage III colon cancer?
    Wang J; Kulaylat M; Rockette H; Hassett J; Rajput A; Dunn KB; Dayton M
    Ann Surg; 2009 Apr; 249(4):559-63. PubMed ID: 19300237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
    van Geelen CM; Westra JL; de Vries EG; Boersma-van Ek W; Zwart N; Hollema H; Boezen HM; Mulder NH; Plukker JT; de Jong S; Kleibeuker JH; Koornstra JJ
    J Clin Oncol; 2006 Nov; 24(31):4998-5004. PubMed ID: 17075118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Operative salvage for locoregional recurrent colon cancer after curative resection: an analysis of 100 cases.
    Bowne WB; Lee B; Wong WD; Ben-Porat L; Shia J; Cohen AM; Enker WE; Guillem JG; Paty PB; Weiser MR
    Dis Colon Rectum; 2005 May; 48(5):897-909. PubMed ID: 15785892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cdc2 as prognostic marker in stage UICC II colon carcinomas.
    Meyer A; Merkel S; Brückl W; Schellerer V; Schildberg C; Campean V; Hohenberger W; Croner RS
    Eur J Cancer; 2009 May; 45(8):1466-73. PubMed ID: 19223178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.
    O'Connell MJ; Campbell ME; Goldberg RM; Grothey A; Seitz JF; Benedetti JK; André T; Haller DG; Sargent DJ
    J Clin Oncol; 2008 May; 26(14):2336-41. PubMed ID: 18467725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.
    Marisa L; de Reyniès A; Duval A; Selves J; Gaub MP; Vescovo L; Etienne-Grimaldi MC; Schiappa R; Guenot D; Ayadi M; Kirzin S; Chazal M; Fléjou JF; Benchimol D; Berger A; Lagarde A; Pencreach E; Piard F; Elias D; Parc Y; Olschwang S; Milano G; Laurent-Puig P; Boige V
    PLoS Med; 2013; 10(5):e1001453. PubMed ID: 23700391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of early-stage colorectal cancer patients at risk of relapse post-resection by immunobead reverse transcription-PCR analysis of peritoneal lavage fluid for malignant cells.
    Lloyd JM; McIver CM; Stephenson SA; Hewett PJ; Rieger N; Hardingham JE
    Clin Cancer Res; 2006 Jan; 12(2):417-23. PubMed ID: 16428481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absence of MMP2 expression correlates with poor clinical outcomes in rectal cancer, and is distinct from MMP1-related outcomes in colon cancer.
    Wong JC; Chan SK; Schaeffer DF; Sagaert X; Lim HJ; Kennecke H; Owen DA; Suh KW; Kim YB; Tai IT
    Clin Cancer Res; 2011 Jun; 17(12):4167-76. PubMed ID: 21531813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular prognostic markers in locally advanced colon cancer.
    Lurje G; Zhang W; Lenz HJ
    Clin Colorectal Cancer; 2007 Nov; 6(10):683-90. PubMed ID: 18039421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene expression profiles in esophageal adenocarcinoma predict survival after resection.
    Pennathur A; Xi L; Litle VR; Gooding WE; Krasinskas A; Landreneau RJ; Godfrey TE; Luketich JD
    J Thorac Cardiovasc Surg; 2013 Feb; 145(2):505-12; discussion 512-3. PubMed ID: 23321130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
    Zaanan A; Fléjou JF; Emile JF; Des GG; Cuilliere-Dartigues P; Malka D; Lecaille C; Validire P; Louvet C; Rougier P; de Gramont A; Bonnetain F; Praz F; Taïeb J
    Clin Cancer Res; 2011 Dec; 17(23):7470-8. PubMed ID: 21998335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant chemotherapy improves survival in patients with American Joint Committee on Cancer stage II colon cancer.
    McKenzie S; Nelson R; Mailey B; Lee W; Chung V; Shibata S; Garcia-Aguilar J; Kim J
    Cancer; 2011 Dec; 117(24):5493-9. PubMed ID: 21692068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
    Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
    Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
    Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT
    J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
    Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM
    J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Defining a high-risk subgroup with colon cancer stages I and II for possible adjuvant therapy.
    Gertler R; Rosenberg R; Schuster T; Friess H
    Eur J Cancer; 2009 Nov; 45(17):2992-9. PubMed ID: 19682890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular profiling and risk stratification of adenocarcinoma of the colon.
    Mutch MG
    J Surg Oncol; 2007 Dec; 96(8):693-703. PubMed ID: 18081153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature.
    Mook S; Knauer M; Bueno-de-Mesquita JM; Retel VP; Wesseling J; Linn SC; Van't Veer LJ; Rutgers EJ
    Ann Surg Oncol; 2010 May; 17(5):1406-13. PubMed ID: 20094918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.